Study guide
4.3 Performance Status Scales & Organ Function Assessment
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
4.3 Performance Status Scales & Organ Function Assessment
Key Takeaways Explain This Topic AI
ECOG performance status (0 to 5) and Karnofsky Performance Scale (100% to 0%) quantify functional capacity and independently predict antineoplastic toxicity, chemotherapy tolerance, and overall survival; poor baseline PS (ECOG 3-4) is generally a contraindication to cytotoxic regimens, except in rapidly progressive, highly chemosensitive, potentially curable malignancies.
Carboplatin dosing utilizes the Calvert formula (Dose = Target AUC x [GFR + 25]); when estimated creatinine clearance (CrCl) is used for GFR, the FDA strongly recommends capping estimated CrCl at 125 mL/min to prevent catastrophic myelosuppressive overdosing in patients with supranormal renal clearance.
Chemotherapeutic dose adjustments for renal impairment are critical for renally eliminated agents (e.g., cisplatin contraindicated if CrCl <50-60 mL/min; pemetrexed contraindicated if CrCl <45 mL/min; capecitabine requires 25% dose reduction for CrCl 30-50 mL/min and is contraindicated if CrCl <30 mL/min).
Hepatically metabolized and biliary-eliminated antineoplastics (e.g., doxorubicin, docetaxel, paclitaxel, vinca alkaloids, irinotecan) require empirical dose reductions based on total bilirubin and transaminase elevations; docetaxel carries a black-box warning for treatment-related mortality in patients with transaminases >1.5x ULN co-occurring with alkaline phosphatase >2.5x ULN.
Organ-specific safety gating mandates baseline and serial monitoring of left ventricular ejection fraction (LVEF) for anthracyclines (lifetime cumulative doxorubicin limit 450-550 mg/m^2) and HER2 inhibitors (hold for absolute LVEF <50% with >=10% decline from baseline), as well as diffusing capacity (DLCO) for bleomycin (lifetime limit 400 units).
Last updated: August 2026
Performance Status Scales & Organ Function Assessment
Appropriate selection and safe dosing of antineoplastic pharmacotherapy requires rigorous baseline clinical assessment of the patient's functional physiological reserve and major organ elimination pathways. In oncology clinical practice, chronological age is a poor surrogate for biological fitness. The Board Certified Oncology Pharmacist (BCOP) plays a pivotal role in evaluating performance status scales, calculating precise renal clearance thresholds, adjusting doses for hepatic dysfunction, and implementing baseline organ safety gating (cardiac and pulmonary surveillance) to optimize therapeutic index and prevent fatal toxicities.
1. Functional Performance Status Assessment
Performance status (PS) is an objective, standardized quantification of a cancer patient's general well-being and daily functional autonomy. It is one of the most powerful independent prognostic indicators of treatment-related toxicity, radiographic response, and overall survival. +---------------------------------------------------------------------------------------------------+
- | PERFORMANCE STATUS SCALES & EQUIVALENCIES |
- | |
- | [ECOG / ZUBROD SCALE] [KARNOFSKY PERFORMANCE (KPS)] |
- | |
- | * Grade 0: Fully active; able to carry on all * 100%: Normal; no complaints |
- | pre-disease performance without restriction. * 90%: Normal activity; minor s/sx |
- | |
- | * Grade 1: Restricted in strenuous activity; * 80%: Normal activity with effort |
- | ambulatory and able to carry out light/sedentary work. * 70%: Cares for self; unable to work|
- | |
- | * Grade 2: Ambulatory and capable of all self-care; * 60%: Requires occasional assist |
- | unable to work; up and about >50% of waking hours. * 50%: Requires considerable assist |
- | |
- | * Grade 3: Capable of limited self-care; confined to * 40%: Disabled; requires spec care |
- | bed or chair >50% of waking hours. * 30%: Severely disabled; hospital |
- | |
- | * Grade 4: Completely disabled; cannot carry on any * 20%: Very sick; active supportive |
- | self-care; totally confined to bed or chair. * 10%: Moribund; rapidly fatal |
- | |
- | * Grade 5: Dead. * 0%: Dead. |
- +---------------------------------------------------------------------------------------------------+
- Clinical Decision-Making & Trial Eligibility
ECOG 0–1 (KPS 80%–100%): Standard candidates for aggressive, multi-agent cytotoxic chemotherapy regimens, intensive induction protocols, and clinical trial enrollment.
ECOG 2 (KPS 60%–70%): "Borderline" physiological fitness. Candidates for dose-attenuated cytotoxic regimens, doublet rather than triplet chemotherapy (e.g., in metastatic pancreatic cancer, gemcitabine + nab-paclitaxel preferred over FOLFIRINOX), or single-agent targeted/immunotherapy.
ECOG 3–4 (KPS 10%–40%): High risk of early treatment-related mortality and profound toxicity. Generally a contraindication to cytotoxic chemotherapy; management centers on palliative radiation, targeted therapy (if non-toxic driver mutation exists), or best supportive / hospice care.
Important
The 'Chemosensitive Reversibility' Exception in Poor Performance Status: There is a critical exception to the rule that ECOG 3–4 patients should not receive cytotoxic chemotherapy: rapidly progressive, highly chemosensitive, potentially curable malignancies where poor performance status is driven directly by acute tumor burden rather than end-stage organ failure or chronic frailty. In conditions such as aggressive Non-Hodgkin Lymphoma (DLBCL, Burkitt), Acute Leukemias (APL, AML, ALL), Small Cell Lung Cancer with Superior Vena Cava Syndrome, and Testicular Germ Cell Tumors , prompt initiation of full-dose systemic chemotherapy can reverse organ compromise and restore performance status rapidly.
2. Renal Function Assessment & Antineoplastic Dosing
Accurate renal function estimation is paramount because antineoplastics possess exceptionally narrow therapeutic windows. Underestimation leads to disease under-treatment, while overestimation causes fatal myelosuppression, mucositis, or nephrotoxicity. +---------------------------------------------------------------------------------------------------+
- | RENAL FUNCTION ASSESSMENT IN ONCOLOGY PRACTICE |
- | |
- | [COCKCROFT-GAULT EQUATION] |
- | |
- | (140 - Age [years]) x Weight [kg] |
- | CrCl (mL/min) = ------------------------------------ x (0.85 if Female) |
- | 72 x Serum Creatinine [mg/dL] |
- | |
- | ============================================================================================= |
- | * Weight Selection Rules: |
- | - Underweight (Actual < IBW): Use ACTUAL Body Weight (ABW). |
- | - Normal Weight (Actual within 100%-120% IBW): Use IBW or ABW per institutional protocol. |
- | - Obese (Actual > 120%-130% IBW): Use Adjusted Body Weight (AdjBW = IBW + 0.4 x [ABW - IBW]). |
- | * Serum Creatinine (SCr) Rounding Controversy: |
- | - Rounding low SCr (e.g., 0.4 to 0.6 mg/dL) up to 0.8 or 1.0 mg/dL in elderly or cachectic |
- | patients is NOT recommended by FDA or CPND guidelines because it systematically underdoses |
- | curative chemotherapy (e.g., carboplatin AUC). Use clinical judgment! |
- +---------------------------------------------------------------------------------------------------+
- The Calvert Formula for Carboplatin Dosing
Carboplatin clearance is directly proportional to glomerular filtration rate (GFR). Unlike most cytotoxic agents that are dosed by body surface area ( m g / m 2 mg/m^2 m g / m 2 ), carboplatin is dosed using target area under the concentration-time curve (AUC): Total Carboplatin Dose (mg) = Target AUC ( mg ⋅ min / mL ) × ( GFR [ mL/min ] + 25 ) \text{Total Carboplatin Dose (mg)} = \text{Target AUC } (\text{mg}\cdot\text{min}/\text{mL}) \times (\text{GFR } [\text{mL/min}] + 25) Total Carboplatin Dose (mg) = Target AUC ( mg ⋅ min / mL ) × ( GFR [ mL/min ] + 25 ) +---------------------------------------------------------------------------------------------------+
- | THE FDA MAXIMUM GFR CAP IN CARBOPLATIN DOSING |
- | |
- | To avoid severe, life-threatening thrombocytopenia and neutropenia in patients with |
- | supranormal renal clearance or underestimated SCr, the FDA established that: |
- | **The estimated GFR / CrCl used in the Calvert formula must NOT exceed 125 mL/min.** |
- | |
- | [MAXIMUM ALLOWABLE CARBOPLATIN DOSES] |
- | * Target AUC 6 Cap: 6 x (125 + 25) = 900 mg |
- | * Target AUC 5 Cap: 5 x (125 + 25) = 750 mg |
- | * Target AUC 4 Cap: 4 x (125 + 25) = 600 mg |
- | * Target AUC 2 Cap: 2 x (125 + 25) = 300 mg (common weekly radiosensitizing dose) |
- +---------------------------------------------------------------------------------------------------+
- Renally Eliminated Antineoplastics & Specific Toxicity Gating
Antineoplastic Agent Renal Clearance (%) Critical Renal Cut-Offs & Gating Clinical Pharmacy Action & Toxicity Mitigation
Cisplatin ~90% renal CrCl < 50 − 60 mL/min \text{CrCl} <50-60\text{ mL/min} CrCl < 50 − 60 mL/min Cisplatin is contraindicated; switch to carboplatin. Requires aggressive pre- and post-hydration ( 1 − 2 L 1-2\text{ L} 1 − 2 L normal saline with 20 mEq KCl + 1 g MgSO 4 20\text{ mEq KCl} + 1\text{ g } \text{MgSO}_4 20 mEq KCl + 1 g MgSO 4 ) +/- mannitol to maintain diuresis > 100 mL/hr >100\text{ mL/hr} > 100 mL/hr .
High-Dose Methotrexate (HD-MTX ≥ 1 g/m 2 \ge 1\text{ g/m}^2 ≥ 1 g/m 2 ) ~90% renal Baseline CrCl < 60 mL/min \text{CrCl} <60\text{ mL/min} CrCl < 60 mL/min Contraindicated. Methotrexate precipitates in renal tubules at acidic pH. Mandatory pre-alkalinization (IV NaHCO 3 \text{NaHCO}_3 NaHCO 3 , maintain urine pH ≥ 7.0 \text{pH} \ge 7.0 pH ≥ 7.0 ), hyperhydration ( ≥ 2.5 − 3.0 L/m 2 / day \ge 2.5-3.0\text{ L/m}^2/\text{day} ≥ 2.5 − 3.0 L/m 2 / day ), and leucovorin rescue nomogram. Glucarpidase for clearance failure + nephrotoxicity.
Pemetrexed ~70%–90% unchanged in urine CrCl < 45 mL/min \text{CrCl} <45\text{ mL/min} CrCl < 45 mL/min Not recommended / contraindicated due to severe myelosuppression and fatal mucositis. Mandatory folic acid + vitamin B12 supplementation. Hold short-acting NSAIDs for 2 days before, day of, and 2 days after pemetrexed if CrCl 45–79 mL/min (5 days for long-acting NSAIDs like naproxen/piroxicam).
Capecitabine ~70% urinary excretion of metabolites CrCl 30 − 50 mL/min \text{CrCl } 30-50\text{ mL/min} CrCl 30 − 50 mL/min :; Reduce dose by 25%.; CrCl < 30 mL/min \text{CrCl} <30\text{ mL/min} CrCl < 30 mL/min :; CONTRAINDICATED. Dose reduction avoids severe diarrhea, stomatitis, and hand-foot syndrome.
Bleomycin ~60%–70% renal CrCl 40 − 50 mL/min \text{CrCl } 40-50\text{ mL/min} CrCl 40 − 50 mL/min :; Reduce by 30%.; CrCl 10 − 39 mL/min \text{CrCl } 10-39\text{ mL/min} CrCl 10 − 39 mL/min :; Reduce by 50%. Decreased clearance triggers severe endothelial lung damage and fatal pulmonary fibrosis.
Lenalidomide / Pomalidomide Lenalidomide ~80% unchanged in urine Lenalidomide:; CrCl 30 − 50 \text{CrCl } 30-50 CrCl 30 − 50 : 10 mg/day.; CrCl < 30 \text{CrCl } <30 CrCl < 30 : 15 mg Q48H or 5 mg/day.; HD: 5 mg post-HD. Dose adjustments prevent Grade 4 neutropenia and thrombocytopenia in multiple myeloma.
3. Hepatic Function Assessment & Dose Adjustments
The liver is the primary site of clearance for lipophilic antineoplastics, anthracyclines, taxanes, vinca alkaloids, and targeted tyrosine kinase inhibitors.
Child-Pugh Score & NCI-ODWG Criteria +---------------------------------------------------------------------------------------------------+
- | CHILD-PUGH CLASSIFICATION SYSTEM |
- | |
- | PARAMETER SCORED 1 POINT 2 POINTS 3 POINTS |
- | * Total Bilirubin (mg/dL) < 2.0 2.0 - 3.0 > 3.0 |
- | * Serum Albumin (g/dL) > 3.5 2.8 - 3.5 < 2.8 |
- | * Prothrombin Time (INR prolongation) < 1.7 1.7 - 2.3 > 2.3 |
- | * Ascites None Slight / Controlled Severe / Refr.|
- | * Hepatic Encephalopathy None Grade 1 - 2 Grade 3 - 4 |
- | |
- | ============================================================================================= |
- | * Class A (5-6 points): Well-compensated; eligible for systemic HCC therapy (Atezolizumab + |
- | Bevacizumab, Durvalumab + Tremelimumab, Sorafenib, Lenvatinib). |
- | * Class B (7-9 points): Significant functional compromise; clinical trials typically exclude. |
- | * Class C (10-15 points): Decompensated cirrhosis; systemic antineoplastic therapy CONTRAIND. |
- +---------------------------------------------------------------------------------------------------+
- National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) Hepatic Criteria
- Normal: Bilirubin ≤ ULN \le \text{ULN} ≤ ULN and AST ≤ ULN \text{AST} \le \text{ULN} AST ≤ ULN
Mild: Bilirubin ≤ ULN \le \text{ULN} ≤ ULN and AST > ULN \text{AST} > \text{ULN} AST > ULN , OR Bilirubin 1.0 − 1.5 × ULN 1.0-1.5 \times \text{ULN} 1.0 − 1.5 × ULN and any AST
- Moderate: Bilirubin > 1.5 − 3.0 × ULN >1.5-3.0 \times \text{ULN} > 1.5 − 3.0 × ULN and any AST
- Severe: Bilirubin > 3.0 × ULN >3.0 \times \text{ULN} > 3.0 × ULN and any AST
Critical Hepatically Eliminated Antineoplastic Modifications +---------------------------------------------------------------------------------------------------+
- | HEPATIC DRUG ADJUSTMENT SUMMARY FOR HIGH-YIELD ONCOLYTICS |
- | |
- | [DOXORUBICIN / DAUNORUBICIN] |
- | * Biliary excretion (~40%-50%). |
- | * Bilirubin 1.2 - 3.0 mg/dL ---> Administer 50% of standard dose. |
- | * Bilirubin 3.1 - 5.0 mg/dL ---> Administer 25% of standard dose (75% reduction). |
- | * Bilirubin > 5.0 mg/dL ---> HOLD / CONTRAINDICATED. |
- | |
- | [DOCETAXEL] |
- | * Hepatic CYP3A4 metabolism & biliary excretion. |
- | * BLACK-BOX WARNING: Increased treatment-related mortality, severe neutropenia, and febrile |
- | neutropenia in patients with AST/ALT > 1.5x ULN CONCOMITANT with Alk Phos > 2.5x ULN. |
- | * Severe hepatic impairment: CONTRAINDICATED. |
- | |
- | [PACLITAXEL] |
- | * CYP2C8 / CYP3A4 metabolism. |
- | * Transaminases > 2x ULN or Bilirubin > 1.5 mg/dL: Reduce dose by 20%-50% or hold. |
- | |
- | [VINCRISTINE / VINBLASTINE] |
- | * Biliary clearance. |
- | * Bilirubin 1.5 - 3.0 mg/dL ---> Administer 50% of dose. |
- | * Bilirubin > 3.0 mg/dL ---> Administer 25% of dose or HOLD (prevents fatal neurotoxicity/ |
- | paralytic ileus). |
- | |
- | [IRINOTECAN] |
- | * Glucuronidated by hepatic UGT1A1 to inactive SN-38G. |
- | * Elevated bilirubin (>1.5-2.0 mg/dL) severely impairs SN-38 clearance, triggering life- |
- | threatening neutropenia and severe refractory diarrhea; avoid in moderate/severe dysfunction. |
- +---------------------------------------------------------------------------------------------------+
- 4. Baseline Cardiopulmonary & Organ Fitness Surveillance
Baseline organ safety gating establishes mandatory physiological thresholds prior to administering antineoplastics with irreversible cumulative organ toxicities.
Left Ventricular Ejection Fraction (LVEF) Gating +---------------------------------------------------------------------------------------------------+
- | CARDIOTOXICITY GATING & SURVEILLANCE |
- | |
- | [ANTHRACYCLINES (Doxorubicin)] [HER2-TARGETED THERAPY (Trastuzumab, Pertuzumab)] |
- | * Type I Cardiotoxicity (Irreversible * Type II Cardiotoxicity (Reversible myocyte |
- | myocyte death, vacuolization, fibrosis). stunning, not dose-dependent). |
- | * Lifetime Cumulative Dose Limit: * Baseline LVEF must be >= 50% - 55%. |
- | 450 - 550 mg/m^2 (Doxorubicin). * Monitoring: Repeat Echo / MUGA every 3 months. |
- | * Dexrazoxane (Zinecard) cardioprotection: * GATING RULE: Hold therapy if LVEF drops |
- | FDA approved for metastatic breast cancer >=10 percentage points from baseline AND is <50%. |
- | who have received >=300 mg/m^2 doxorubicin* Re-evaluate in 3-4 weeks; resume if LVEF |
- | and require ongoing anthracycline therapy. recovers to >=50% or baseline. |
- +---------------------------------------------------------------------------------------------------+
- Pulmonary Function Testing (PFTs) & DLCO
Bleomycin Pulmonary Toxicity:
Generates reactive oxygen species that cleave DNA; pulmonary tissue lacks the inactivating enzyme bleomycin hydrolase , rendering lungs uniquely susceptible to oxidative injury.
Cumulative Lifetime Dose Limit: 400 Units (risk of fatal interstitial pulmonary fibrosis increases exponentially above 400 units).
PFT Surveillance: Baseline Diffusing Capacity of the Lung for Carbon Monoxide ( DLCO ) and spirometry. Bleomycin must be held or permanently discontinued if DLCO drops by ≥ 20 % \ge 20\% ≥ 20% from baseline or falls < 30 % – 35 % <30\%\text{--}35\% < 30% – 35% of predicted.
Perioperative Caution: Avoid high inspired oxygen concentrations ( FiO 2 > 0.30 \text{FiO}_2 >0.30 FiO 2 > 0.30 ) during surgical anesthesia in patients with prior bleomycin exposure, as hyperoxia precipitates acute respiratory distress syndrome (ARDS).
Antibody-Drug Conjugates (ADCs) & Interstitial Lung Disease (ILD):
Trastuzumab Deruxtecan (T-DXd): Carries black-box warning for ILD / pneumonitis. Grade 1 (asymptomatic radiographic) requires drug hold until complete resolution and consideration of systemic corticosteroids; Grade ≥ 2 \ge 2 ≥ 2 (symptomatic) mandates permanent drug discontinuation and immediate high-dose corticosteroid therapy (prednisone ≥ 1 mg/kg/day \ge 1\text{ mg/kg/day} ≥ 1 mg/kg/day ).